Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Pharmaceutical Technology on MSN
MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor
This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer ...
Big pharma bets on KRAS G12D as oncology race intensifies Drugmakers chase tough G12D target with degraders and pan-KRAS ...
A preclinical study shows that combining KRASG12D inhibition with CTLA-4 blockade dismantles a TGF-beta-driven regulatory T ...
A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...
A study led by University of Cincinnati Cancer Center researchers sheds new light on how pancreatic cancer cells resist treatment and points to potential new combination therapies to make treatments ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
G12C therapies broaden patient reach, while biomarker-led combinations and US-focused launches can unlock unmet demand and strengthen competitive positioning.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ...
SAN DIEGO -- Treatment with investigational elisrasib, a next-generation KRAS G12C inhibitor, showed efficacy in patients with advanced non-small cell lung cancer (NSCLC) with and without previous ...
The total potential aggregate value of the transaction, including the upfront payment, is $2.13 billion. SPR2015 is an oral, potent, selective molecular-glue KRAS G12D (ON) inhibitor showing nanomolar ...
According to Asfar Azmi, PhD, results from the study showed that the PCNA inhibitor AOH1996 was synergistic with KRAS inhibitors of all classes. The combination of the first-in-class PCNA inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results